Tvardi Therapeutics, Inc.
TVRD
$3.75
-$0.16-4.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.84M | 7.39M | 4.97M | 4.46M | 2.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.96M | 29.70M | 28.01M | 28.11M | 21.97M |
| Operating Income | -29.96M | -29.70M | -28.01M | -28.11M | -21.97M |
| Income Before Tax | -23.65M | -23.63M | -34.77M | -29.40M | -21.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.65 | -23.63 | -34.77 | -29.40 | -21.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.65M | -23.63M | -34.77M | -29.40M | -21.04M |
| EBIT | -29.96M | -29.70M | -28.01M | -28.11M | -21.97M |
| EBITDA | -29.87M | -29.61M | -27.92M | -28.01M | -21.87M |
| EPS Basic | -3.57 | -5.12 | -8.33 | -7.49 | -6.19 |
| Normalized Basic EPS | -2.23 | -3.20 | -5.21 | -4.68 | -3.87 |
| EPS Diluted | -5.08 | -6.63 | -8.33 | -7.49 | -6.19 |
| Normalized Diluted EPS | -2.24 | -3.21 | -5.21 | -4.68 | -3.87 |
| Average Basic Shares Outstanding | 30.42M | 23.62M | 17.95M | 17.94M | 17.92M |
| Average Diluted Shares Outstanding | 30.63M | 23.83M | 17.95M | 17.94M | 17.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |